Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Liabilities and Shareholders Equity (2024 - 2025)

Carlsmed's Liabilities and Shareholders Equity history spans 2 years, with the latest figure at $130.1 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 151.08% year-over-year to $130.1 million; the TTM value through Dec 2025 reached $370.1 million, changed N/A, while the annual FY2025 figure was $130.1 million, 151.08% up from the prior year.
  • Liabilities and Shareholders Equity reached $130.1 million in Q4 2025 per CARL's latest filing, down from $134.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $134.9 million in Q3 2025 to a low of $51.8 million in Q4 2024.